《大行報告》瑞銀下調康方生物-B(09926.HK)目標價至26.68元 評級「買入」
瑞銀髮表研究報告指出,康方生物-B(09926.HK)在2022年美國臨牀腫瘤學會(ASCO)年會上披露了用於治療各種腫瘤的藥物AK104、AK112和AK109研究數據,該行認爲有關的1期及2期臨牀試驗的安全性和有效性數據十分令人鼓舞。
該行偏好康方生物於開發雙特異性抗體(BsAb)的差異化及其全面的管線,並期望公司關鍵候選藥物獲得許可的機會。對其目標價由29.6元降至26.68元,維持「買入」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.